SARS-CoV-2-directed T cell Response in Convalescent and Vaccinated Individuals
![]() |
Understanding both the humoral (neutralizing antibodies) and cellular (T cell) immune response to SARS-CoV-2 infection or vaccination is essential for managing the COVID-19 pandemic. The widely reported phenomenon that humoral immunity wanes following both convalescence and vaccination has underscored the importance of assessing T cell-mediated protection against SARS-CoV-2. A concise yet detailed review by Bertoletti et al. analyzes the present data related to characterization of SARS-CoV-2-specific T cells and both their protective and pathological actions (1). The authors also survey the literature related to memory T cells induced by either natural infection or vaccination. In a second perspective, an original study by Jordan et al. reports that T cells generated by SARS-CoV-2 infection or vaccination demonstrate protective immunity against at least two VOCs (i.e., Alpha and Delta), offering encouraging insight that this may extend to other VOCs (2).
GeneTex has developed a comprehensive catalog of reagents for SARS-CoV-2/COVID-19 research, including antibodies that may detect the Omicron VOC based on immunogen sequence analysis. Please see the images below identifying several of these products and click here for more information.
|
GeneTex’s SARS-CoV-2 Antibodies Predicted to Detect the Omicron Variant |
|
|
|
|
||||||||||||||||||||
|
Reference: |
| Cell Mol Immunol. 2021 Oct;18(10):2307-2312. |
| Cell Mol Immunol. 2021 Nov;18(11):2554-2556. |

![Spike RBD antibody [HL257] (GTX635692)](/upload/media/MarketingMaterial/Newsletter/2021/OmicronVariant/255x255_01.jpg)
![Spike S1 antibody [HL1] (GTX635656)](/upload/media/MarketingMaterial/Newsletter/2021/OmicronVariant/255x255_03.jpg)
![Spike S2 antibody [HL237] (GTX635693)](/upload/media/MarketingMaterial/Newsletter/2021/OmicronVariant/255x255_02.jpg)
![Spike antibody [1A9] (GTX632604)](/upload/media/MarketingMaterial/Newsletter/2021/OmicronVariant/255x255_04.jpg)